Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
osteoporosis
Biotech
Bain-backed Angitia drops lead spinal fusion candidate
The musculoskeletal outfit has scrapped AGA111, terminating a phase 3 study of the recombinant protein in patients undergoing spinal fusion surgery.
Darren Incorvaia
Jun 30, 2026 4:56pm
Angitia raises $130M to advance bone-building bispecifics
Feb 5, 2026 10:17am
Angitia raises $120M series C to fund 3 musculoskeletal trials
Dec 11, 2024 9:40am
FDA clears vibrating belt to boost brittle bones
Jan 22, 2024 9:09am
Malaria drug identified by AI protects and builds bone in mice
Oct 18, 2023 8:00am
Nanox nets FDA clearance for osteoporosis and spine fracture AI
May 2, 2022 2:51pm
